The bar to get 2-73 for Rett approved is very, very low as there are no treatments available. Anavex has fast-track for Rett. The scores displayed yesterday were pretty stunning. With just Rett approved this is a $40-50 SP. I wont get in Alz price tag but we are in the $100s (if not over $1k) if we ever receive approval for alz, but that could be a year or so away before we see data. Dont want to get to far ahead and pie in the sky type valuations. We are just not there yet, but may be this time next year. Rett, however, is very, very close to approval.
The market has priced this wrong, always has. Thats where the real money is made...the market isnt always correct in pricing a stock, and finding stocks that are currently heavily "discounted" is how real wealth is made. The fact that Anavex has based at 16.85ish tells me everything. Everyone was waiting for the gap to fill. It never did. If it was possible it would have been done in August or Sept during the lull in the news cycle and a bad market. We have multiple catalyst on tap before the years end (and the market is in a much more favorable position with some very good earnings coming out, pretty much in all sectors) Missling confirmed this yesterday. I know you are a trader and not a investor, but "28" will look like a very good entry point 1 year from today. All IMO of course. Good luck.
Market Data 
Markets 
AI
